Analysis of Circulating MYCN DNA in Serum Samples Obtained From Patients With Neuroblastoma
- Perform in a blind study a multicentric study by analyzing serum from patients at
diagnosis (with a known tumour MYCN status determined in the COG reference lab), in
order to confirm our previous data and to define the most appropriate MYCN/control
ratio cutoff capable of determining positive and negative cases.
- Define the limits of the procedure in non-metastatic patients and in those with reduced
tumor burden (INSS stage 1 and 2).
OUTLINE: Circulating DNA is extracted from serum. PCR amplification of MYCN is performed and
analyzed by agarose gel electrophoresis. Real-time quantitative PCR is also performed.
Most appropriate MYCN/control ratio cutoff capable of determining positive and negative cases of neuroblastoma
Michael D. Hogarty, MD
Children's Hospital of Philadelphia
United States: Federal Government